Deciphera Pharmaceuticals Inc is a United States-based company. The Company is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. Its switch-control kinase inhibitor platform and applies research and development in kinase biology. The Company design kinase inhibitors to target the switch pocket region of the kinase with the goal of developing potentially transformative medicines through patient-inspired approach.

Employees

355

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-10 EDT			5-day change	1st Jan Change
25.59 ^USD	+0.08%		-.--%	-

06-17	Deciphera Pharmaceuticals, LLC Doses First Patient In Pivotal Phase 3 INTREPID Study Of Sapablursen In Polycythemia Vera	CI
03-26	Ono Pharmaceutical Co., Ltd. Submits Application for Approval of Ripretinib in Japan	CI

Market Cap	2.21B 1.93B 1.78B 1.66B 3.14B 211B 3.19B 21.34B 8.3B 104B 8.31B 8.13B 357B	P/E 2022	-6.92x	P/E 2023	-7.04x
Enterprise Value	1.89B 1.65B 1.52B 1.41B 2.68B 180B 2.72B 18.19B 7.07B 88.26B 7.08B 6.93B 304B	EV / Sales 2022	5,951,009x	EV / Sales 2023	5,909,487x
Free-Float	71.62%	Yield 2022 *	-	Yield 2023	-

06-17	Deciphera Pharmaceuticals, LLC Doses First Patient In Pivotal Phase 3 INTREPID Study Of Sapablursen In Polycythemia Vera	CI
03-26	Ono Pharmaceutical Co., Ltd. Submits Application for Approval of Ripretinib in Japan	CI
02-17	Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL	CI
12-06	Deciphera Pharmaceuticals Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemiaera at the 67th American Society of Hematology Annual Meeting	CI
25-07-28	Deciphera Pharmaceuticals, Llc Announces Positive Chmp Opinion Forromvimza?? (Vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor	CI
25-02-14	Ono Pharmaceutical Co., Ltd. Announces U.S. Food and Drug Administration Approval of Deciphera's Romvimza?? for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor	CI
24-06-11	Ono Pharmaceutical Closes Deciphera Deal for About $2.4 Billion	DJ
24-06-11	Deciphera Pharmaceuticals, Inc. Announces Board and Committee Changes	CI
24-06-11	Deciphera Pharmaceuticals Acquired by Ono Pharmaceutical for $2.4 Billion	MT
24-06-10	Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index	CI
24-06-10	Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P Global BMI Index	CI
24-06-10	Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P TMI Index	CI
24-06-10	Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P Biotechnology Select Industry Index	CI

24-04-30	Barclays Upgrades Deciphera Pharmaceuticals to Equalweight From Underweight, Price Target is $26	MT
24-04-30	Leerink Downgrades Deciphera Pharmaceuticals to Market Perform, Price Target at $25.60	MT
24-04-30	JMP Downgrades Deciphera Pharmaceuticals to Market Perform	MT
24-04-29	JonesTrading Downgrades Deciphera Pharmaceuticals to Hold From Buy, Adjusts Price Target to $25.60 From $16	MT
24-04-29	Jefferies Downgrades Deciphera Pharmaceuticals to Hold From Buy, Trims Price Target to $25.60 From $26	MT

Deciphera Pharmaceuticals, Inc. Stock

Stocks

DCPH

US24344T1016

Biotechnology & Medical Research

Valuation: Deciphera Pharmaceuticals, Inc.

Latest news : Deciphera Pharmaceuticals, Inc.

Analysts' recommendations: Deciphera Pharmaceuticals, Inc.

Press Releases: Deciphera Pharmaceuticals, Inc.

News in other languages: Deciphera Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Deciphera Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

24-06-03	Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet	BU
24-05-01	DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH	BU
24-04-29	Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion	BU
24-04-09	Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum	BU
24-02-27	Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences	BU

22-01-14	En los barrios más pobres de Cuba, jóvenes podrían enfrentar décadas de cárcel tras las protestas
21-11-30	Barbados renuncia a la reina de Inglaterra para convertirse en una república

Manager	Title	Age	Since
Ryota Udagawa CEO	Chief Executive Officer	-	2024-10-31
Rodrigo Ruiz Soto CTO	Chief Tech/Sci/R&D Officer	-	2016-12-31
Dashyant Dhanak CTO	Chief Tech/Sci/R&D Officer	63	2023-09-04

Director	Title	Age	Since
Toichi Takino BRD	Director/Board Member	57	2024-06-10
Masayuki Tanigawa BRD	Director/Board Member	-	2024-06-10

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-06-10	Dashyant Dhanak	Free	Chief Technology Officer	345,001	0.3990%
24-06-10	Susan Kelley	Issuer sale	Director	85,339	0.0987%
24-06-10	Ron Squarer	Issuer sale	Chairman	66,066	0.0764%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DECIPHERA PHARMACEUTICALS, INC.	+0.08%	-.--%	-.--%	+82.26%	2.21B
ARGENX SE	+0.68%	+5.92%	+77.86%	+139.22%	59.1B
WUXI APPTEC CO., LTD.	+2.32%	+5.03%	+75.26%	+91.40%	55.19B
BIONTECH SE	+3.86%	+6.93%	-11.32%	-9.53%	24.67B
INSMED INCORPORATED	+4.30%	+7.95%	+14.11%	+437.83%	24.19B
WUXI BIOLOGICS (CAYMAN) INC.	+4.74%	+13.68%	+43.36%	-4.67%	19.69B
GENMAB A/S	-0.29%	+9.78%	+43.90%	-28.41%	17.56B
PHARMAESSENTIA CORPORATION	0.00%	+20.78%	+186.15%	+361.42%	16.22B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.72%	+19.38%	+37.85%	-	14.84B
EXELIXIS, INC.	+3.50%	+1.97%	+21.02%	+191.95%	14.04B
Average	+2.59%	+7.71%	+48.82%	+140.16%	24.77B
Weighted average by Cap.	+2.44%	+6.42%	+57.80%	+136.46%

	2022	2023
Net sales	134.04 117.17 107.68 100.37 190.38 12.76K 193.27 1.29K 502.55 6.27K 503.12 492.31 21.62K	163.36 142.81 131.24 122.33 232.02 15.55K 235.54 1.58K 612.49 7.65K 613.17 600.01 26.35K
Net income	-179M -156M -144M -134M -254M -17.04B -258M -1.73B -671M -8.37B -672M -657M -28.86B	-195M -170M -157M -146M -277M -18.56B -281M -1.88B -731M -9.12B -732M -716M -31.44B
Net Debt	-310M -271M -249M -232M -440M -29.51B -447M -2.99B -1.16B -14.51B -1.16B -1.14B -49.98B	-327M -286M -263M -245M -465M -31.14B -472M -3.15B -1.23B -15.31B -1.23B -1.2B -52.74B

3 years	9.9	25.61
5 years	6.51	37.99
10 years	6.51	71.11